Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HY6725 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| HY6725 | EXPERIMENTAL | It's an injection solution. SAD part for subcutaneous dosing in 7 cohorts, including 3mg, 10mg, 30mg, 90mg, 150mg, 300mg and 450mg with only one administration on Day 1 of each cohort. MAD part for subcutaneous dosing in 3 cohorts, including 150mg, 300mg and 450mg with two administrations on Day 1 and Day 30 of each cohort. |
| placebo | PLACEBO_COMPARATOR | It's same injection solution just without active ingredient compared with HY6725. SAD part for subcutaneous dosing in 7 cohorts, including 3mg, 10mg, 30mg, 90mg, 150mg, 300mg and 450mg with only one administration on Day 1 of each cohort. MAD part for subcutaneous dosing in 3 cohorts, including 150mg, 300mg and 450mg with two administrations on Day 1 and Day 30 of each cohort. |
| Name | Type | Description |
|---|---|---|
| HY6725 | BIOLOGICAL | HY6725 is an injection solution with 120mg/ml per vial. SAD part for subcutaneous dosing in 7 cohorts, including 3mg, 10mg, 30mg, 90mg, 150mg, 300mg and 450mg with only one administration on Day 1 of each cohort. MAD part for subcutaneous dosing in 3 cohorts, including 150mg, 300mg and 450mg with two administrations on Day 1 and Day 30 of each cohort. |
| Placebo Control | OTHER | A vial with 1ml injection solution contain same ingredient except HY6725 compared with HY6725 solution. |
Inclusion Criteria: 1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent. 2. Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital sign assessme...
HY6725 is an investigational monoclonal antibody being developed by Genelux Corporation. It is currently in Phase 1 clinical development for use in healthy adult participants. The drug is being studied to evaluate its safety, tolerability, and pharmacokinetics.
HY6725 is being studied for use in healthy adult participants. The ongoing Phase 1 trial is designed to evaluate the safety, tolerability, and pharmacokinetics of the drug. It is not yet approved for any medical condition and remains in clinical development.
HY6725 is being developed by Genelux Corporation, a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol GNLX. Genelux is conducting a Phase 1 clinical trial to evaluate the drug's safety and tolerability in healthy participants.
HY6725 is in Phase 1 clinical development. The drug is currently being evaluated in a Phase 1 trial that is recruiting participants. It is an investigational drug and has not been approved by regulatory authorities for any use.
HY6725 is being studied in a Phase 1 clinical trial with the identifier NCT07262281. The trial is titled "Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult Participants" and is currently recruiting in Australia. The study plans to enroll 74 healthy adult participants.